# US 2025/0325541 A1 · Methods of dispersing aripiprazole injectable preparations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0325541 A1
- Document ID: US20250325541A1
- Status: Published application
- Kind: A1
- Application number: 19/220,457
- Filed: 2025-05-28
- Published: 2025-10-23
- Earliest claimed: 2023-03-17
- Assignees: Otsuka Pharmaceutical Co., Ltd.
- Applicants: Otsuka Pharmaceutical Co., Ltd.
- Inventors: Kazuya NAKAMURA; Yoko SAKAMOTO; Daiki KANEKO
- Web page: https://patentgrep.com/patent/US20250325541A1

## CPC

- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/10: Dispersions; Emulsions
- A61K 47/02: Inorganic compounds
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/38: Cellulose; Derivatives thereof
- A61M 5/31513: {Piston constructions to improve sealing or sliding}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/24: Antidepressants
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure is directed to methods of dispersing injectable preparations comprising aripiprazole or a salt thereof. Methods of enhancing slidability of containers comprising long-acting injectable preparations comprising aripiprazole or a salt thereof, the methods comprising dispersing ingredients comprised in the preparations before administration, aripiprazole injectable preparations to be administered after the dispersion, methods of administration thereof, and use thereof are provided.

## Claims

### Claim at position 1

1-24. (canceled)

### Claim 25

A method of enhancing slidability of a container comprising an aripiprazole, or salt thereof, long-acting injectable preparation, the method comprising:
dispersing a gel of the preparation to form a sol or a suspension of the preparation in the container before administration,
wherein long-acting is about two months.

### Claim 26 (depends on 25)

The method according to claim 25, wherein the dispersing step comprises tapping the container at least 8 times and shaking the container for at least 8 seconds.

### Claim 27 (depends on 25)

The method according to claim 25, wherein the dispersing step comprises tapping the container at least 10 times and shaking the container for at least 10 seconds.

### Claim 28 (depends on 25)

The method according to claim 25, wherein a sliding resistance of the container after the dispersing step is 30N or less.

### Claim 29 (depends on 25)

The method according to claim 25, wherein the container is a prefilled syringe.

### Claim 30 (depends on 25)

The method according to claim 25, wherein the preparation is for intramuscular administration and for treating a subject having schizophrenia or bipolar I disorder.

### Claim 31 (depends on 25)

The method according to claim 25, wherein the preparation comprises aripiprazole in an amount ranging from about 700 mg to about 1000 mg.

### Claim 32 (depends on 31)

The method according to claim 31, wherein the container comprises an amount of 2.0 mL or more of the preparation per single administration.

### Claim 33 (depends on 25)

The method according to claim 25, wherein the preparation is white to off-white and comprises:
720 mg or 960 mg of anhydrous aripiprazole,
carboxymethylcellulose sodium,
polyethylene glycol 400,
sodium chloride,
sodium phosphate monobasic monohydrate, and
sodium hydroxide.

### Claim 34 (depends on 25)

The method according to claim 25, further comprising after dispersing, administering the preparation in the container to a subject in need thereof.

### Claim 35 (depends on 25)

A method for treating a subject having schizophrenia or bipolar I disorder, comprising slowly administering the injectable preparation subjected to the method according to claim 25 to the subject, wherein slowly is over about 0.5 seconds or more.

### Claim 36

A method for treating a subject having schizophrenia or bipolar I disorder, comprising dispersing an injectable preparation in a form of a gel to a sol or a suspension of aripiprazole or a salt thereof in a container, and intramuscularly administering to a subject the injectable preparation, wherein the subject is administered the injectable preparation about once every two months.

### Claim 37 (depends on 36)

The method according to claim 36, wherein the dispersing step comprises tapping the container at least 8 times and shaking the container for at least 8 seconds.

### Claim 38 (depends on 36)

The method according to claim 36, wherein a sliding resistance of the container after the dispersing step is 30N or less.

### Claim 39 (depends on 36)

The method according to claim 36, wherein the container is a prefilled syringe.

### Claim 40 (depends on 36)

The method according to claim 36, wherein the administration is at a gluteal muscle of the subject.

### Claim 41 (depends on 36)

The method according to claim 36, wherein the administration of about once every two months results in a total amount of aripiprazole ranging from about 700 mg to about 1000 mg to the subject.

### Claim 42 (depends on 36)

The method according to claim 36, wherein the container comprises an amount of 2.0 mL or more of the preparation per single administration.

### Claim 43 (depends on 36)

The method according to claim 36, wherein the preparation is white to off-white and comprises:
720 mg or 960 mg of anhydrous aripiprazole,
carboxymethylcellulose sodium,
polyethylene glycol 400,
sodium chloride,
sodium phosphate monobasic monohydrate, and
sodium hydroxide.

### Claim 44 (depends on 36)

The method according to claim 36, wherein the administration comprises slowly injecting the injectable preparation to the subject and slowly is over about 0.5 seconds or more.

### Claim 45

A long-acting injectable preparation for intramuscular administration for treating a subject having schizophrenia or bipolar I disorder, comprising aripiprazole or a salt thereof in a container, wherein the preparation is in a form of a gel upon static conditions and reverts to a sol or a suspension when dispersed and long-acting is about two months.

### Claim 46 (depends on 45)

The preparation according to claim 45, wherein the preparation comprises a total amount of aripiprazole ranging from about 700 mg to about 1000 mg.

### Claim 47 (depends on 45)

The preparation according to claim 45, wherein the container is a prefilled syringe for the administration in an amount of 2.0 mL or more per single administration.

### Claim 48 (depends on 45)

The preparation according to claim 45, wherein the preparation is white to off-white and comprises:
720 mg or 960 mg of anhydrous aripiprazole,
carboxymethylcellulose sodium,
polyethylene glycol 400,
sodium chloride,
sodium phosphate monobasic monohydrate, and
sodium hydroxide.
